Isaac Haq

Isaac Haq is a seasoned professional in the investment and life sciences sectors, currently serving as a Board Member and Portfolio Management Lead at Biodextris and contributing to the Investment Team at ArchiMed since 2018, where roles have progressed from Analyst to Associate Director. Additionally, Isaac held the position of Head of Strategy & Corporate Development at Pluristyx, Inc. during a sabbatical from ArchiMed, focusing on iPSC-based technologies. Experience includes serving as a Board Observer for multiple companies, such as Polyplus-transfection S.A., Xpress Biologics, and CLEAN BIOLOGICS. Previous roles include Junior Analyst at Motive Partners and Business Development Junior Analyst at Biotechspert. Isaac Haq holds a BA in Medicine with Cognitive Neuroscience from the University of Cambridge, an MSc in Finance and Private Equity from The London School of Economics and Political Science, and is pursuing a PhD in Health Economics & Policy at Lancaster University.